Fig. 3From: Comparing diagnostic and prognostic performance of two-gene promoter methylation panels in tissue biopsies and urines of prostate cancer patientsDisease-specific survival curves according to standard clinicopathological parameters [histologic grade group, clinical stage, PSA serum levels, CAPRA Score, and D’Amico risk group classification] and epigenetic marks [miR-34b/c and panel #2] in prostate biopsy (cohort #1)Back to article page